Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Rating of "Hold" by Analysts

Key Points

• Analysts give Centessa a consensus “Hold” rating (1 sell, 8 hold, 5 buy) with an average 12‑month price target of $40.00.
• The company saw heavy insider selling last quarter — insiders sold 349,073 shares worth about $9.43 million, leaving insiders with roughly 7.09% ownership.
• Centessa has a market cap of $6.11 billion, a 52‑week range of $10.95–$40.26, and reported a quarterly loss of $0.48 per share, missing the consensus loss estimate of $0.38.

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) has earned a consensus recommendation of "Hold" from the fourteen brokerages that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $40.00.

A number of research firms have recently issued reports on CNTA. Weiss Ratings reissued a "sell (d-)" rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. TD Cowen reissued a "buy" rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 14th. Needham & Company LLC lowered shares of Centessa Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Tuesday, March 31st. Stephens lowered shares of Centessa Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, March 31st. Finally, Leerink Partners lowered shares of Centessa Pharmaceuticals from an "outperform" rating to a "hold" rating and raised their price objective for the company from $36.00 to $40.00 in a research report on Wednesday, April 1st.

Insider Activity at Centessa Pharmaceuticals

In related news, insider Iqbal J. Hussain sold 38,951 shares of the firm's stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $25.15, for a total transaction of $979,617.65. Following the transaction, the insider owned 57,645 shares of the company's stock, valued at approximately $1,449,771.75. This trade represents a 40.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gregory M. Weinhoff sold 73,196 shares of the firm's stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the transaction, the insider directly owned 65,925 shares in the company, valued at approximately $1,735,805.25. The trade was a 52.61% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 349,073 shares of company stock valued at $9,429,412. 7.09% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. TD Waterhouse Canada Inc. bought a new position in Centessa Pharmaceuticals during the fourth quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd acquired a new position in Centessa Pharmaceuticals during the fourth quarter valued at approximately $36,000. T. Rowe Price Investment Management Inc. grew its holdings in Centessa Pharmaceuticals by 7,580.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company's stock valued at $39,000 after purchasing an additional 1,516 shares during the last quarter. Wells Fargo & Company MN grew its holdings in Centessa Pharmaceuticals by 42.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company's stock valued at $85,000 after purchasing an additional 1,008 shares during the last quarter. Finally, Knott David M Jr acquired a new position in Centessa Pharmaceuticals during the fourth quarter valued at approximately $100,000. Institutional investors own 82.01% of the company's stock.

Centessa Pharmaceuticals Price Performance

NASDAQ CNTA opened at $39.53 on Friday. The company has a 50 day simple moving average of $29.83 and a 200-day simple moving average of $26.61. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.57 and a quick ratio of 8.57. The firm has a market capitalization of $6.11 billion, a price-to-earnings ratio of -26.89 and a beta of 1.25. Centessa Pharmaceuticals has a 52-week low of $10.95 and a 52-week high of $40.26.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.10). Equities research analysts predict that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.